Risk of healthcare partners including Ascella failing to obtain EUA and meet product development targets
First written in FY2021. 1 of 3 entries say "Worsened", first in FY2022. Latest entry: FY2024.
The whole theme swung hardest in 2023: 4 of 17 companies on the "Worse" side.
31 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「The healthcare development company that is our partner is proceeding with product development in accordance with its plan. However, if the business fails to progress as planned, the company’s business and operating results may be affected.」
The company continues to disclose the risk that product development and business progress at its healthcare partner may fail to proceed as planned. - FY2022WorsenedAnnual report
「The healthcare product development company that is our partner is seeking emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its testing equipment. However, if product development fails to progress or the business fails to progress as planned, the company’s business and operating results may be affected.」
While continuing to disclose the risks associated with Ascella’s development of testing equipment and acquisition of EUA, the company explains that delays have occurred in funding for the next growth phase and in funding based on the initial plan. - FY2021First statedAnnual report
「The healthcare product development company that is our partner is seeking emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its testing equipment. However, if product development fails to progress or the business fails to progress as planned, the company’s business and operating results may be affected.」
The company has disclosed as a new risk the potential impact if its healthcare partner’s product development or acquisition of EUA for its testing equipment fails to progress as planned.